Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 4/20 | 0.57 |
| ▸ | HDAC3 known ✓ | O15379 | 1/20 | 0.57 |
| ▸ | HDAC4 known ✓ | P56524 | 1/20 | 0.57 |
| ▸ | HDAC1 known ✓ | Q13547 | 1/20 | 0.57 |
| ▸ | HDAC7 known ✓ | Q8WUI4 | 1/20 | 0.57 |
| ▸ | HDAC2 known ✓ | Q92769 | 1/20 | 0.57 |
| ▸ | HDAC10 known ✓ | Q969S8 | 1/20 | 0.57 |
| ▸ | HDAC11 known ✓ | Q96DB2 | 1/20 | 0.57 |
| ▸ | HDAC8 known ✓ | Q9BY41 | 1/20 | 0.57 |
| ▸ | HDAC6 known ✓ | Q9UBN7 | 1/20 | 0.57 |
| ▸ | HDAC9 known ✓ | Q9UKV0 | 1/20 | 0.57 |
| ▸ | HDAC5 known ✓ | Q9UQL6 | 1/20 | 0.57 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 4/20 | 0.56 |
| ▸ | ACHE known ✓ | P22303 | 2/20 | 0.54 |
| ▸ | CCR5 known ✓ | P51681 | 2/20 | 0.53 |
| ▸ | BCHE known ✓ | P06276 | 1/20 | 0.53 |
| ▸ | DRD4 known ✓ | P21917 | 3/20 | 0.52 |
| ▸ | DRD3 known ✓ | P35462 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2588250 | 0.98 | MEN1 (0.65) | MEN1KMT2ADRD2HDAC3HDAC4 | |
| SCHEMBL3153917 | 0.92 | MEN1 (0.74) | MEN1KMT2ADRD2HDAC3HDAC4 | |
| SCHEMBL1002852 | 0.87 | MEN1 (0.81) | MEN1KMT2ADRD2SIGMAR1ACHE | |
| Hydrochloric Acid SCHEMBL27545537 | 0.85 | SIGMAR1 (0.64) | MEN1KMT2ASIGMAR1ACHECCR5 | |
| SCHEMBL7571134 | 0.84 | MEN1 (0.88) | MEN1KMT2ADRD2SIGMAR1ACHE | |
| SCHEMBL9070278 | 0.84 | MEN1 (0.67) | MEN1KMT2ADRD2HDAC3HDAC4 | |
| SCHEMBL27542888 | 0.83 | SIGMAR1 (0.66) | MEN1KMT2ASIGMAR1ACHECCR5 | |
| Hydrochloric Acid SCHEMBL11501364 | 0.83 | MEN1 (0.66) | MEN1KMT2ADRD2SIGMAR1ACHE | |
| SCHEMBL11453030 | 0.83 | POLB (0.67) | MEN1KMT2ADRD2SIGMAR1ACHE | |
| SCHEMBL8659907 | 0.83 | MEN1 (0.65) | MEN1KMT2ADRD2HDAC3HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160081997-A1 | PIPERIDINE/PIPERAZINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2016-03-24 | — | — | US | disclosed |
| US-9227935-B2 | Piperidine/piperazine derivatives | JANSSEN PHARMACEUTICAL N.V. (BE) | 2016-01-05 | — | — | US | disclosed |
| US-20150087629-A1 | PIPERIDINE/PIPERAZINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2015-03-26 | — | — | US | disclosed |
| US-8981094-B2 | Piperidine/piperazine derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2015-03-17 | — | — | US | disclosed |
| EP-2152270-B1 | PIPERIDINE/PIPERAZINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2015-03-04 | — | — | EP | disclosed |
| US-8946228-B2 | Piperidine/piperazine derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2015-02-03 | — | — | US | disclosed |
| EP-2155198-B1 | Piperidine/piperazine derivatives | JANSSEN PHARMACEUTICA NV (BE) | 2014-08-13 | — | — | EP | disclosed |
| CN-101678013-B | Piperidine/piperazine derivatives | JANSSEN PHARMACEUTICA NV | 2014-05-07 | — | — | CN | disclosed |
| US-8354402-B2 | Polyarylcarboxamides useful as lipid lowering agents | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-01-15 | — | — | US | disclosed |
| US-20110269747-A1 | POLYARYLCARBOXAMIDES USEFUL AS LIPID LOWERING AGENTS | MEERPOEL LIEVEN | 2011-11-03 | — | — | US | disclosed |
| US-7253157-B2 | Polyarylcarboxamides useful as lipid lowering agents | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-08-07 | — | — | US | disclosed |
| EP-1806341-A2 | (+)Phenyl-(4-{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-piperidin-1-yl)-acetic acid methyl ester as lipid lowering agent | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-11 | — | — | EP | disclosed |
| US-20070082888-A1 | POLYARYLCARBOXAMIDES USEFUL AS LIPID LOWERING AGENTS | MEERPOEL LIEVEN | 2007-04-12 | — | — | US | disclosed |
| US-7169796-B2 | Polyarylcarboxamides useful as lipid lowering agents | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-01-30 | — | — | US | disclosed |
| US-20060241113-A1 | Polyarylcarboxamides useful as lipid lowering agents | MEERPOEL LIEVEN | 2006-10-26 | — | — | US | disclosed |
| US-20050159402-A1 | Polyarylcarboxamides useful as lipid lowering agents | MEERPOEL LIEVEN (BE) | 2005-07-21 | — | — | US | disclosed |
| US-6878724-B2 | Polyarylcarboxamides useful as lipid lowering agents | JANSSEN-PHARMACEUTICA N.V. (BE) | 2005-04-12 | — | — | US | disclosed |
| US-20040014971-A1 | Polyarylcarboxamides useful as lipid lowering agents | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-01-22 | — | — | US | disclosed |
| EP-1317431-A2 | POLYARYLCARBOXAMIDES USEFUL AS LIPID LOWERING AGENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-06-11 | — | — | EP | disclosed |
| WO-2002020501-A2 | POLYARYLCARBOXAMIDES USEFUL AS LIPID LOWERING AGENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2002-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050159402-A1 | Polyarylcarboxamides useful as lipid lowering agents | LIPC, PNLIP, APOB | DRD2 4425/4885HDAC3 329/4885HDAC4 799/4885 |
| US-20060241113-A1 | Polyarylcarboxamides useful as lipid lowering agents | LIPC, PNLIP, APOB | DRD2 4425/4885HDAC3 329/4885HDAC4 799/4885 |
| US-20110269747-A1 | POLYARYLCARBOXAMIDES USEFUL AS LIPID LOWERING AGENTS | LIPC, PNLIP, APOB | DRD2 4425/4885HDAC3 329/4885HDAC4 799/4885 |
| US-20150087629-A1 | PIPERIDINE/PIPERAZINE DERIVATIVES | DGAT1, NAT1, SOAT1 | DRD2 279/4885HDAC3 207/4885HDAC4 1457/4885 |
| US-20040014971-A1 | Polyarylcarboxamides useful as lipid lowering agents | SREBF1, LIPC, CPT1A | DRD2 4495/4885HDAC3 446/4885HDAC4 1000/4885 |
| US-20070082888-A1 | POLYARYLCARBOXAMIDES USEFUL AS LIPID LOWERING AGENTS | LIPC, PNLIP, APOB | DRD2 4425/4885HDAC3 329/4885HDAC4 799/4885 |
| US-20160081997-A1 | PIPERIDINE/PIPERAZINE DERIVATIVES | DGAT1, DGAT2, SOAT1 | DRD2 244/4885HDAC3 258/4885HDAC4 1688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.